PHS
PFM Health Sciences Portfolio holdings
AUM
$1.15B
This Quarter Return
-5.43%
1 Year Return
+21.39%
3 Year Return
+130.75%
5 Year Return
+265.32%
10 Year Return
+1,236.5%
AUM
$2.59B
AUM Growth
+$2.59B
(-9.7%)
Cap. Flow
-$29.5M
Cap. Flow
% of AUM
-1.14%
Top 10 Holdings %
Top 10 Hldgs %
36.86%
Holding
80
New
9
Increased
17
Reduced
15
Closed
11
Top Buys
| 1 |
Jazz Pharmaceuticals
JAZZ
|
$80.4M |
| 2 |
Johnson & Johnson
JNJ
|
$46.1M |
| 3 |
Becton Dickinson
BDX
|
$41.9M |
| 4 |
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
|
$34.1M |
| 5 |
Molina Healthcare
MOH
|
$24.6M |
Top Sells
| 1 |
AbbVie
ABBV
|
$124M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$46.3M |
| 3 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$41.5M |
| 4 |
Neurocrine Biosciences
NBIX
|
$33.6M |
| 5 |
HCA Healthcare
HCA
|
$28.9M |
Sector Composition
| 1 | Healthcare | 95.79% |
| 2 | Financials | 0.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Outset Medical
OM
$247M
| $128M | 4.77% | 2,810,686 -129,569 | -4% | -$5.88M |
|
|
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $115M | 4.3% | 1,091,840 | – | – |
|
3
Arcus Biosciences
RCUS
$1.13B
| $108M | 4.05% | 3,431,010 | – | – |
|
|
4
Johnson & Johnson
JNJ
$427B
| $104M | 3.88% | 584,883 +259,911 | +80% | +$46.1M |
|
5
Centene
CNC
$14.3B
| $93.7M | 3.5% | 1,112,480 | – | – |
|
6
Cytokinetics
CYTK
$4.23B
| $90.7M | 3.39% | 2,465,016 | – | – |
|
7
Eli Lilly
LLY
$657B
| $85.5M | 3.2% | 298,643 | – | – |
|
|
8
Jazz Pharmaceuticals
JAZZ
$7.75B
| $80.4M | 3.01% | +516,406 | New | +$80.4M |
|
9
iRhythm Technologies
IRTC
$5.46B
| $77.7M | 2.91% | 493,721 -30,261 | -6% | -$4.77M |
|
10
Humana
HUM
$36.5B
| $72.3M | 2.7% | 166,066 +26,646 | +19% | +$11.6M |
|
11
Avantor
AVTR
$9.18B
| $70.3M | 2.63% | 2,079,657 | – | – |
|
12
Pfizer
PFE
$141B
| $69.5M | 2.6% | 1,343,384 | – | – |
|
13
Universal Health Services
UHS
$11.6B
| $64M | 2.39% | 441,336 -34,004 | -7% | -$4.93M |
|
14
UnitedHealth
UNH
$281B
| $56.9M | 2.13% | 111,554 | – | – |
|
15
BioMarin Pharmaceuticals
BMRN
$11.2B
| $55.4M | 2.07% | 718,495 +253,555 | +55% | +$19.5M |
|
16
Danaher
DHR
$147B
| $51.5M | 1.93% | 175,690 | – | – |
|
17
IQVIA
IQV
$32.4B
| $51.3M | 1.92% | 221,696 -16,343 | -7% | -$3.78M |
|
18
ICU Medical
ICUI
$3.15B
| $49.1M | 1.84% | 220,587 | – | – |
|
|
19
Molina Healthcare
MOH
$9.8B
| $48M | 1.79% | 143,779 +73,691 | +105% | +$24.6M |
|
20
Myriad Genetics
MYGN
$593M
| $47.4M | 1.77% | 1,882,357 -143,324 | -7% | -$3.61M |
|
|
NVRO
21
DELISTED
NEVRO CORP.
NVRO
| $47M | 1.76% | 649,513 +164,378 | +34% | +$11.9M |
|
22
Tenet Healthcare
THC
$16.3B
| $46.8M | 1.75% | 544,583 +18,656 | +4% | +$1.6M |
|
|
23
Becton Dickinson
BDX
$55.3B
| $41.9M | 1.57% | +157,593 | New | +$41.9M |
|
24
Dynavax Technologies
DVAX
$1.19B
| $41.3M | 1.54% | 3,805,370 | – | – |
|
25
Erasca
ERAS
$445M
| $41.2M | 1.54% | 4,791,406 -399,999 | -8% | -$3.44M |
|